CONTACT
+91 80 2808 2808
info@biocon.com
About Us
Overview
Who we are
Our Key Priorities
Board of Directors
Key Management Team
Our Legacy
Fact Sheet
Our Stories
Scientific Publications
Awards & Recognition
Products
Overview
Key Therapeutic Areas
Generics
Biosimilars
Novel Biologics
Branded Formulations
Businesses
Overview
Generics
Executive Leadership Team
API
Generic Formulations
Quality & Compliance
Manufacturing Operations
Research & Development
Regulatory Affairs
Biosimilars
Biocon Biologics
Board of Directors
Executive Leadership Team
Global Portfolio
Wide Global Footprint
Quality & Compliance
Partners
Global Scale Manufacturing
Research & Development
Branded Formulations
Novel Biologics
Biocon and Novels
Novels Pipeline
Research Services
Investors
Overview
Financial Fact Sheet
Financial Information
Annual Reports
Quarterly Reports
Key Figures (Annual & Quarterly)
Earnings Call Recordings
Earnings Call Transcripts
Subsidiary Financials
Investor Presentations
Corporate Governance
Overview
Board of Directors
Board Committees
Our Leadership
Corporate Structure
Company History & Milestones
Governance Documents & Policies
Share Information
Share Graph
Share Series
Share Price Look Up
Investment Calculator
Share Price Alerts
Fragulizer
Dividends
Unclaimed and Unpaid Dividend
IEPF
Shareholder Services
Annual General Meeting
Postal Ballot
Investor Feedback
Investor FAQ
Miscellaneous Communication
Financial Calendar
Stock Exchange Disclosures
Notice of Board Meeting
Investors Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements & Disclosures
Analyst Coverage
Code Of Conduct
Email Subscription Services
Investor Contact
Disclosures under Regulation 46 of LODR
Careers
Overview
Working With Us
Now Hiring
Functions
Our Culture
Diversity And Inclusion
Learning & Development
Awards & Recognition
Benefits
Meet Our Employees
Career FAQ’s
Responsibility
Overview
Biocon Foundation
Social Impact
Partners
Grant-in-Aid
Awards and Recognition
Sustainability
Safer Workplace
An Environment of Change
Environmental Clearance
EHS Certifications
Biocon Academy
News
Overview
Press Releases
Company Statements
Media Stories
Image Gallery
Video Gallery
Events & Calendar
Media Contacts
More+
Contact Us
Blog
For Patients
Biocon in Malaysia
Group Companies
Syngene
Biocon BIologics
Bicara
Biocon Academy
Biocon
/
Investor Relations
/
Stock Exchange Disclosures
/
Company Statement
PRESS RELEASE
STOCK EXCHANGE DISCLOSURES
Notice of Board Meeting
Investor Meeting
Press Release
Company Statement
Shareholding Pattern
Corporate Governance Report
Newspaper Advertisement
RPT Disclosure
Other Announcements and Disclosures
FY 2023-24
June-23
03-June
Biocon Pharma Limited’s facility at Bengaluru Concludes USFDA Surveillance and Inspection, With Zero Observations
May-23
20-May
Biocon’s API facility at Hyderabad Concludes USFDA Inspection, with Zero Observations
April-23
28-Apr
Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
FY 2022-23
February-23
12-Feb
USFDA issues a CRL for the Biologics License Application for Bevacizumab
January-23
07-Jan
USFDA issues a CRL for the Biologics License Application for Insulin-R
December-22
22-Dec
Biocon Limited receives the final inspection report from EDQM
October-22
21-Oct
Biocon Biologics Insulins Facility in Malaysia Receives EU GMP Certification
07-Oct
Biocon Foundation Receives ‘Mahatma Award 2022 for Excellence in Social Good’
August-22
31-Aug
USFDA Consolidated Biocon Biologics Notification
July-22
05-July
Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru
June-22
21-June
Biocon Biologics issues a statement in response to the media reports related to bribery allegations
May-22
03-May
HPRA Completes Audit of Biocon Biologics New mAbs Drug Substance Facility in Bengaluru
FY 2021-22
January-22
08-Jan
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
September-21
25-Sep
Biocon Biologics Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
08-Sep
Biocon Limited enters into a settlement agreement with Celgene Corp.
FY 2020-21
28-Apr
Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.
26-Apr
Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
12-Apr
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK
Feb-21
12-Feb
Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
Dec-20
25-Dec
Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020
14-Dec
Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
May-20
12-May
Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification
08-May
Biocon’s Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection
Apr-20
16-Apr
Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed
ARCHIVES
FY: From April 1 – March 31
Know more
about us
>> Generics
>> Biocon Academy
>> Biocon Malaysia
NOVEL BIOLOGICS
BIOSIMILARS
RESEARCH SERVICES
OUR CULTURE
BIOCON FOUNDATION